Migraine medicine spent the last decade building drugs around a single peptide. A new registry measured that peptide in the blood and found less of it in people with migraine, not more.
The peptide is calcitonin gene-related peptide, or CGRP, a short chain of amino acids that nerve cells release to widen blood vessels and pass along pain signals. It sits at the center of how migraine is now treated. Alpha-CGRP ↗ is the form human nerves make and the one the newest preventive drugs are designed to shut down.
The study, published June 12 in Neurology ↗, drew on the Registry for Migraine and compared 588 adults who get migraines with 147 healthy controls matched one-to-four on age, sex, body weight, and how long each blood sample had sat in storage. Nearly nine in ten participants in both groups were women. Blood was drawn from the arm and CGRP measured twice per sample with a high-sensitivity assay.
The expected result was higher CGRP in the migraine group. The standard account of migraine has the peptide flooding the bloodstream, and several earlier and smaller studies reported exactly that. This one found the reverse. Median plasma CGRP was 125 picomoles per liter in the migraine group against 151 in controls, about 17 percent lower (p less than 0.001). A picomole per liter is just a measure of how much of the peptide is dissolved in a fixed amount of blood.
The gap did not budge across the cuts that should have mattered. People with chronic migraine looked like people with occasional migraine. Migraine with aura looked like migraine without. Blood drawn during an attack looked like blood drawn between attacks. Whether or not someone was on a preventive drug made no difference. When the analysis was narrowed to participants who happened to be headache-free at the moment of the draw, CGRP was still lower across every subgroup.
That is a hard result for the idea of a migraine blood test. The appeal of CGRP as a biomarker was the hope that a simple blood draw could track disease activity or flag who would respond to treatment. A marker that runs slightly lower in patients, does not move with attack state, and has no clinical predictors is not measuring the disease in any useful way. The authors concluded that plasma CGRP has limited utility as a disease biomarker.
None of this undercuts the drugs. The anti-CGRP antibodies (erenumab, sold as Aimovig; fremanezumab, Ajovy; galcanezumab, Emgality; eptinezumab, Vyepti) and the gepants (rimegepant, marketed as Nurtec; atogepant, Qulipta) work by blocking CGRP where it acts, on the trigeminal nerves and the vessels around the brain, during the cascade that produces a headache. That local, on-demand signaling is not the same thing as the resting amount floating in a vein, and a drug that quiets the first does not need the second to be high. A target you can drug and a marker you can measure in blood are different problems, and CGRP just showed how far apart they can sit.
The result also fits an uncomfortable pattern in the CGRP story. When peptidemodel covered CGRP antibodies in cluster headache ↗, the same drugs that reshaped migraine care barely separated from placebo. The biology around this peptide keeps refusing to be simple. Alpha-CGRP acts through the CALCR/RAMP receptor family ↗, and the registry is a reminder that knowing the target does not mean the blood level tells you anything.